Men's Health News

RSS

Acrux reports Phase III trial results evaluating AXIRON for testosterone deficiency

Australian company, Acrux, today announced positive results from a Phase III trial evaluating the safety and efficacy of AXIRON™ in 155 men with testosterone deficiency (hypogonadism), across 26 sites in six countries.

29 Sep 2009

Statistical modeling used to estimate benefits and risks of PSA screening

Men largely make decisions about prostate cancer screening based on conversations with their clinicians, but these discussions often do not include information about the risks of testing in addition to the benefits, according to a report in the September 28 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

29 Sep 2009

Radiation treatment after prostate cancer surgery eradicates recurrent cancer

The largest single-institution study of its kind has found few complications in prostate cancer patients treated with radiotherapy after surgery to remove the prostate. Men in this study received radiotherapy after a prostate-specific antigen (PSA) test following surgery indicated their cancer had recurred.

29 Sep 2009

Androgen deficiency linked to diabetes and cardiovascular diseases

Researchers from Boston University School of Medicine (BUSM) in collaboration with researchers from Lahey Clinic Northshore, Peabody, Mass., believe that androgen deficiency might be the underlying cause for a variety of common clinical conditions, including diabetes, erectile dysfunction, metabolic syndrome and cardiovascular disease (CVD). These findings appear in the September/October issue of the Journal of Andrology.

25 Sep 2009

Three-day meeting to discuss breakthroughs in prostate cancer

Nearly of 300 of the world’s leading researchers focused on the problem of prostate cancer will begin a three-day meeting today to discuss the latest scientific data and breakthroughs in prostate cancer. The meeting, held in Incline Village at Lake Tahoe in Nevada, is the 16th Scientific Retreat sponsored by the Prostate Cancer Foundation (PCF).

25 Sep 2009

Chemicals found in breast milk adversly affect the fetal testis

A comparison of breast milk samples from Denmark and Finland revealed a significant difference in environmental chemicals which have previously been implicated in testicular cancer or in adversely affecting development of the fetal testis in humans and animals. This finding is published today in the International Journal of Andrology.

25 Sep 2009

Study compares benefits of laparoscopic and traditional open surgery for prostate cancer

The more things change, the more they stay the same, as the proverb goes. A study appearing in an upcoming edition of The Journal of Oncology appears to prove just that. The study compares the benefits of laparoscopic surgery versus traditional open surgery in the treatment of prostate cancer. With traditional surgery, surgeons remove the prostate gland via an incision below the belly button.

24 Sep 2009

Hsp-27 protein: An indicator of prostate cancer progression

In the largest study of its kind, the international team of pathologists studied an initial 4,000 prostate cancer patients over a period of 15 years to further understanding into the natural progression of the disease and how it should be managed. The research, published in the British Journal of Cancer, could be used to develop a blood test to distinguish between aggressive and non-aggressive forms of prostate cancer.

24 Sep 2009

Rescuing immune system cells can reduce risk of prostate cancer

Immune therapies have been explored as a way to treat cancer after it develops. But a new study from the University of Michigan Comprehensive Cancer Center suggests that genetic risk of prostate cancer can be reduced by rescuing critical immune system cells.

24 Sep 2009

Medivation commences patient treatment in clinical trial of MDV3100 in advanced prostate cancer

Medivation, Inc. (Nasdaq: MDVN) today announced treatment of the first patient in a Phase 3 clinical trial of the investigational drug MDV3100 in advanced prostate cancer. Known as AFFIRM, the trial will evaluate the novel androgen receptor antagonist MDV3100 in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy.

24 Sep 2009

Hsp-27 protein helps identify aggressive prostate cancer

CANCER RESEARCH UK scientists have discovered a molecular 'flag' that predicts survival from prostate cancer at diagnosis, reveals a study published in the British Journal of Cancer.

24 Sep 2009

Clothes for women who undergo a mastectomy

One in eight U.S. women will be diagnosed with breast cancer during their lifetime, and currently slightly more than half, 56 percent, undergo mastectomy. Few fashion options exist for those who don’t seek reconstructive surgery or postpone it until after their treatment and recovery — a condition the clothier Wear Ease (www.WearEase.com) seeks to remedy.

21 Sep 2009

Four single-letter variations in SNPs increse prostate cancer risk

deCODE genetics (Nasdaq: DCGN) today announced that a team of its scientists and academic colleagues from Finland, Spain, the Netherlands and the United States have today published the discovery of four novel single-letter variations in the sequence of the human genome (SNPs) conferring increased risk of prostate cancer.

21 Sep 2009

Prostate cancer more prevalent in African-American men

A new guide, Straight Talk for African-American Men and their Families, is now available from the Prostate Cancer Foundation (PCF). It was produced in alliance with Charlie Wilson, famed R&B singer and recent prostate cancer survivor.

19 Sep 2009

Cryosurgery: Primary treatment option for prostate cancer

After years of innovation and intensive research, a team of Binghamton University (BU) researchers working with Cell Preservation Services, Inc., Owego, NY has broken extraordinary new ground in the recognition of cryosurgery as a primary treatment option for prostate cancer.

16 Sep 2009

PCEC to provide free prostate cancer screenings

This September, the Prostate Conditions Education Council reminds men to set aside 10 minutes to take lifesaving measures. In just 10 minutes, the same amount of time it takes to shave their faces, men can be screened for prostate cancer, the second leading cause of death among American men. For one week this month the Prostate Conditions Education Council (PCEC) will be coordinating Prostate Cancer Awareness Week (PCAW), which provides free or low-cost screenings to thousands of men across the United States.

16 Sep 2009

ESHRE's first workshop on male infertility

ESHRE invites you to attend its first workshop on male infertility in Thessaloniki, Greece "Reproductive andrology: linking laboratory to clinical practice". The workshop provides a forum for clinicians and scientists to share research results and discuss new developments.

16 Sep 2009

Research study investigates survival rates of prostate cancer patients across time periods

New research to be published in tomorrow's issue of the Journal of the American Medical Association (JAMA) (Vol. 302, No. 11), by a team at The Cancer Institute of New Jersey (CINJ), shows that men diagnosed with prostate cancer beginning in the early 1990's had significantly improved survival outcomes compared with patients whose cancers were diagnosed in prior decades.

16 Sep 2009

Defective gene is linked to male infertility

Virginia Commonwealth University School of Medicine researchers have discovered a gene involved with the production of sperm that may contribute to male infertility and lead to new approaches to male contraception.

16 Sep 2009

Men and healthcare professionals urged to take proactive approach to prostate cancer

As prostate cancer is the third leading cause of cancer death in European men with more than 300,000 men being diagnosed every year, society needs to commit to changing the way the disease is viewed. Therefore a mini-symposium and lunch meeting are organized on 18 September 2009 in Antwerp on the occasion of the European launch of the Proactive Prostates Initiative, organized as part of Urology Week.

14 Sep 2009